Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3537-3540

  Greenspan, Susan L ^a,b   Rosen, Harold N ^b,c   Parker, Robert A ^b,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Harvard Thorndike General Clinical Research Center   (United States)

^c Department of Medicine

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; COLLAGEN TYPE 1; PEPTIDE DERIVATIVE; PLACEBO;

AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033766628     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.10.3537     Document Type: Article

References (24)

1. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
2. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
3. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
4. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis
5. The predictive value of biochemical markers of bone turnover for bone mineral density in early post-menopausal women treated with hormone replacement or calcium supplementation
6. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
7. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean
8. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel
9. Biochemical markers of bone turnover reflect femoral bone loss in elderly women
10. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links
11. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
12. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study
13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
14. Evidence that serum NTx (collagen type 1 N-telopeptides) can act as an immunochemical marker of bone resorption
15. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
16. Biochemical markers of bone turnover: A look at laboratory tests that reflect bone status
17. Biochemical markers in the assessment of bone disease
18. Diurnal variation of bone mineral turnover in elderly men and women
19. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates
20. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new marker of bone collagen degradation
21. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: Relation to calcium kinetics
22. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy
23. Clinical evaluation of the serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides
24. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women